CLINICAL TRIALS PROFILE FOR SECRETIN SYNTHETIC PORCINE
✉ Email this page to a colleague
All Clinical Trials for secretin synthetic porcine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00065962 ↗ | Secretin for the Treatment of Autism | Completed | National Institute on Deafness and Other Communication Disorders (NIDCD) | Phase 3 | 1999-06-01 | Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms. |
| NCT00065962 ↗ | Secretin for the Treatment of Autism | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 3 | 1999-06-01 | Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms. |
| NCT00620919 ↗ | Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis | Terminated | Massachusetts General Hospital | Phase 1 | 2008-02-01 | 1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Multidetector Computed Tomography (MDCT) of the pancreas. 2. To demonstrate that RG1068-enhanced MDCT improves image quality of the pancreas in patients with chronic pancreatitis. 3. To evaluate if RG1068 enhanced MDCT results in improved delineation of structural abnormalities of the pancreatic duct as compared to non-enhanced MDCT. |
| NCT00621283 ↗ | Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population | Terminated | Massachusetts General Hospital | Phase 1 | 2008-02-01 | 1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography. 2. To demonstrate that RG1068-enhanced MRCP improves image quality relative to unenhanced MRCP in patients with unexplained acute recurrent pancreatitis (ARP) and chronic pancreatitis. 3. To evaluate if the use of RG1068-enhanced MRCP improves structural delineation of the pancreatic duct as compared to the non-enhanced MRCP. 4. To assess pancreatic exocrine function by quantifying pancreatic fluid output into the duodenum and the apparent diffusion coefficient of the pancreas. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for secretin synthetic porcine
Condition Name
Clinical Trial Locations for secretin synthetic porcine
Trials by Country
Clinical Trial Progress for secretin synthetic porcine
Clinical Trial Phase
Clinical Trial Sponsors for secretin synthetic porcine
Sponsor Name
| Sponsor Name for secretin synthetic porcine | |
| Sponsor | Trials |
| Massachusetts General Hospital | 3 |
| National Institute on Deafness and Other Communication Disorders (NIDCD) | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
